AmoyDx Announces Clinical Research Collaboration with AstraZeneca on Targeted Therapy Companion Diagnostics

On April 18, Amoy Diagnostics Co. LTD. announced that it had signed two cooperation agreements with AstraZeneca.

1. The company will jointly advance the registration of its self-developed companion diagnostic product with AstraZeneca for the identification of prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union, and Japan.

2. The company will jointly advance the registration of another self-developed companion diagnostic product with AstraZeneca for identifying breast cancer patients with BRCA mutations in the European region.

Currently, AstraZeneca's PARP inhibitor products include Lynparza.^®(Olaparib), which was jointly developed by AstraZeneca and Merck, and has been approved in multiple countries for the treatment of patients with advanced ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.